Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma

19 May 2017

Abstract excerpt

The identification of driver mutations in melanoma has changed the field of cancer treatment. BRAF and NRAS mutations are predominant in melanoma and lead to overactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways. Selective inhibitors targeting key effectors of the MAPK pathway have revolutionized the treatment of patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to Melanoma and MAPK Pathways
Share to Quinazolinone synthesis and applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28543695
DOI: 10.1002/cncr.30435

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaPMID 28543695Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.Semantic proximity Read ↗

Targeted therapy resistance mechanisms and therapeutic implications in melanoma.Semantic proximity Read ↗

Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.Semantic proximity Read ↗

Targeted Therapy Innovations for Melanoma.Semantic proximity Read ↗

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read ↗

BRAF inhibitors: resistance and the promise of combination treatments for melanomaSemantic proximity Read ↗

Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in MelanomaSemantic proximity Read ↗

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An UpdateSemantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.